SCHEDULE 13G/A: Greenhaven Road Investment Management Discloses 7.8% Passive Stake in Lifecore Biomedical
Beneficial Ownership Statement
Greenhaven Road Investment Management and its affiliated entities have filed an amended Schedule 13G, reporting a passive beneficial ownership of 7.8% in Lifecore Biomedical, Inc.'s common stock as of December 31, 2023.
Summary
- Greenhaven Road Investment Management, L.P., MVM Funds, LLC, Scott Miller, Greenhaven Road Capital Fund 1, L.P., and Greenhaven Road Capital Fund 2, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
- As of December 31, 2023, the Reporting Persons collectively beneficially own 2,366,956 shares of Lifecore Biomedical, Inc. Common Stock.
- This ownership represents 7.8% of the outstanding Common Stock of Lifecore Biomedical, Inc.
- The percentage is calculated based on 30,322,169 shares of Common Stock outstanding as of April 26, 2023, as reported by the Issuer in its Form 10-Q filed on June 2, 2023.
- The filing indicates that the securities were acquired and are held for investment purposes and not with the intent to change or influence the control of the issuer, consistent with a passive investment strategy under Rule 13d-1(b).
Sentiment
Score: 6
Explanation: The filing is largely neutral as it's a routine disclosure of a passive stake. However, the presence of a significant institutional investor can be viewed as a minor positive signal of confidence in the company.
Positives
- The disclosure of a significant passive stake by an investment management firm like Greenhaven Road Investment Management may signal institutional confidence in Lifecore Biomedical, Inc.'s long-term prospects.
- Increased institutional ownership can sometimes lead to greater market liquidity and investor interest in the stock.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain information related to broader industry trends or competitor analysis.
Stakeholder Impact
- Shareholders: The disclosure provides transparency regarding significant institutional ownership, which may influence investor perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2023-04-26 | Date as of which 30,322,169 shares of Common Stock were reported outstanding by Lifecore Biomedical, Inc. in its Form 10-Q. |
| 2023-06-02 | Date Lifecore Biomedical, Inc. filed its Form 10-Q with the SEC, reporting shares outstanding. |
| 2023-12-31 | Date of event which required the filing of this Schedule 13G, reflecting the beneficial ownership stake. |
| 2025-02-14 | Date the Schedule 13G was signed and filed by the Reporting Persons. |
Keywords
Lifecore Biomedical, Greenhaven Road Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.